Cercar
01/10/2022
Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL)
Gonzalez-Barrallo, I, Rubio, VEC, Medina, J, Espana, S, Mujika, K, Majem, M, Aguado, C, Suarez, MAC, Palacio, I, Osterloh, L, Martinez-Fernandez, A, Garcia-Castano, A. Safety of combining dabrafenib plus trametinib in elderly BRAF V600 mutation-positive advanced melanoma patients: real-world data analysis of Spanish patients (ELDERLYMEL). MELANOMA RESEARCH. 2022; 32(5)DOI:10.1097/CMR.0000000000000837. PMID:35762583. IF:2.200(Q3/7D).
01/10/2022
Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events
Alserawan, L, Anguera, G, Atenza, CZ, Lopez, JS, Martinez-Martinez, L, Melia, MR, Sullivan, I, Joaquin, AB, Tarruella, MM, Vidal, S. Association between Changes in the Patterns of Antinuclear Autoantibodies during Immune Checkpoint Inhibition Therapy and the Development of Severe Immune Related Adverse Events. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES. 2022; 23(20)DOI:10.3390/ijms232012641. PMID:36293498. IF:5.600(Q1/3D).
12/09/2022
Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non-small cell lung cancer in Spain
Majem, M, Alvarez, R, Ortega, AL, de Alda, LR, Gordo, R, Garcia, JF, Ivanova-Markova, Y, Gonzalez-Dominguez, A, San Cristobal, RS, Rojo, F. Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non-small cell lung cancer in Spain. Global & Regional Health Technology Assessment. 2022; 9DOI:10.33393/grhta.2022.2449. PMID:36628311. IF:(Q/D).
01/09/2022
Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia
Hwang, TJ, Kesselheim, AS, Tibau, A, Lee, CC, Vokinger, KN. Clinical Benefit and Expedited Approval of Cancer Drugs in the United States, European Union, Switzerland, Japan, Canada, and Australia. JCO Oncology Practice. 2022; 18(9)DOI:10.1200/OP.21.00909. PMID:35731996. IF:4.000(Q2/4D).
01/09/2022
Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy
Casarrubios, M, Provencio, M, Nadal, E, Insa, A, Garcia-Campelo, MD, Lazaro-Quintela, M, Domine, M, Majem, M, Rodriguez-Abreu, D, Martinez-Marti, A, Carpeno, JD, Cobo, M, Vivanco, GL, Del Barco, E, Bernabe, R, Vinolas, N, Aranda, IB, Massuti, B, Sierra-Rodero, B, Martinez-Toledo, C, Fernandez-Miranda, I, Serna-Blanco, R, Romero, A, Calvo, V, Cruz-Bermudez, A. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy. Journal for ImmunoTherapy of Cancer. 2022; 10(9)DOI:10.1136/jitc-2022-005320. PMID:36171009. IF:10.900(Q1/2D).
24/08/2022
In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma
Hernandez, A, Munoz-Marmol, AM, Esteve-Codina, A, Alameda, F, Carrato, C, Pineda, E, Arpi-Llucia, O, Martinez-Garcia, M, Mallo, M, Gut, M, del Barco, S, Gallego, O, Dabad, M, Mesia, C, Bellosillo, B, Domenech, M, Vidal, N, Aldecoa, I, de la Iglesia, N, Balana, C. In silico validation of RNA-Seq results can identify gene fusions with oncogenic potential in glioblastoma. Scientific Reports. 2022; 12(1)DOI:10.1038/s41598-022-18608-8. PMID:36002559. IF:4.600(Q2/4D).